Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

By M. R. Corces-Zimmerman, W. Hong, Irving L. Weissman, B. Medeiros, R. Majeti. Proceedings of the National Academy of Sciences of the United States of America, 2014

717 citations recorded by the source corpus.

Citations in the corpus

The Human Cell Atlas (2017, neutral): “…has been used to study the clonal structure and evolution of tumors in both breast cancer (Wang et al., 2014) and acute lymphoblastic leukemia (Gawad et al., 2014), and to infer the order of earliest mutations that cause acute myeloid leukemia (Corces-Zimmerman et al., 2014; Jan et al., 2012).”
Age-related clonal hematopoiesis associated with adverse outcomes. (2014, neutral): “Preleukemic hematopoietic stem cells harboring only the initiating driver mutation have been found in the bone marrow of patients with acute myeloid leukemia (AML) that is in remission.(9-11) Sequencing studies have identified a set of recurrent mutations in several types of hematologic cancers.”